Olympus Corporation (7733): FY2025 Results Summary — Rebuilding Year as FDA Ship-Holds and Tariffs Weigh on Margin

This article is based on publicly available IR materials and is not a recommendation to buy or sell any specific securities.

Note: Olympus labels the fiscal year ended March 31, 2026 as “FY2026” and the year ending March 31, 2027 as “FY2027”; this article classifies it as FY2025 under the site’s convention for the most recent completed full year, while all figures, tables and segment labels below follow the company’s own presentation.

Olympus Corporation reported full-year FY2026 revenue of 1,010.7 billion yen, up 1% year on year (0% on a constant-currency basis), while operating profit fell 40% to 97.1 billion yen and adjusted operating profit fell 24% to 143.3 billion yen. The company describes FY2026 as a “rebuilding year” in which it absorbed approximately 30 billion yen of net impact from FDA-related import alerts and voluntary ship-holds, alongside U.S. tariff headwinds, an unfavorable sales mix and one-off transformation costs. Fourth-quarter revenue rose 9% year on year to 295.3 billion yen, led by the Gastrointestinal Solutions Division, which the company presents as early evidence that its strategic initiatives are gaining traction. For FY2027, Olympus guides to revenue of 1,055.0 billion yen to 1,076.0 billion yen and an adjusted operating margin of 15.2% to 16.7%.

Consolidated Results (Full-Year Actual)

Revenue increased 1% year on year to 1,010.7 billion yen (0% after FX adjustment). Cost of sales rose 14% to 356.6 billion yen, lifting the cost ratio by 3.8pp to 35.3% of revenue, and SG&A expenses rose 2% to 507.1 billion yen. Other income and expenses widened to negative 46.2 billion yen from negative 26.0 billion yen, and operating profit declined 40% to 97.1 billion yen (9.6% of revenue). Adjusted operating profit — the amount after deducting “Other income” and “Other expenses” from operating profit — fell 24% to 143.3 billion yen, with the adjusted operating margin down 4.7pp to 14.2%. Profit attributable to owners of parent was 68.2 billion yen, down 42%, giving EPS of 61 yen and adjusted EPS of 92 yen. Olympus states that it delivered above its latest guidance range despite the disruption.

Item (billions of yen, except EPS)	FY2026 Full-year	FY2025 Full-year	YoY
Revenue	1,010.7	997.3	+1%
Cost of sales	356.6	313.6	+14%
% of revenue	35.3%	31.4%	+3.8pp
SG&A expenses	507.1	495.7	+2%
% of revenue	50.2%	49.7%	+0.5pp
Other income and expenses	-46.2	-26.0	–
Operating profit	97.1	162.5	-40%
% of revenue	9.6%	16.3%	-6.7pp
Adjusted operating profit	143.3	188.5	-24%
% of revenue	14.2%	18.9%	-4.7pp
Profit before tax	94.0	159.1	-41%
Profit attributable to owners of parent	68.2	117.9	-42%
EPS	¥61	¥103	-40%
Adjusted EPS	¥92	¥117	-21%

The bridge of consolidated adjusted operating profit from 188.5 billion yen to 143.3 billion yen shows a change in sales of +1.2 billion yen, a change in cost of sales of -37.5 billion yen, a change in SG&A expenses of -5.2 billion yen and an impact of foreign exchange and other items (including equity method) of -3.7 billion yen. Within these, the net impact from FDA-related import alerts and voluntary ship-holds was approximately -30 billion yen, and the impact of increased U.S. tariffs was approximately -25 billion yen excluding mitigation effects (approximately -18 billion yen including mitigation). Olympus states that, excluding these effects, underlying margin performance was largely stable.

Segment Results

The Gastrointestinal Solutions Division (GIS) grew revenue 3% to 697.4 billion yen (+2% after FX adjustment), but adjusted operating profit declined 13% to 164.4 billion yen and the segment’s adjusted operating margin fell 4.6pp to 23.6%. The Surgical and Interventional Solutions Division (SIS) saw revenue decline 3% to 313.1 billion yen (-4% after FX adjustment) and posted an operating loss of 15.0 billion yen, with adjusted operating profit down 97% to 0.8 billion yen, reflecting mainly the FDA-related import alerts and ship-holds of certain products. In the fourth quarter, GIS revenue rose 16% year on year to 210.1 billion yen (+10% constant currency), with GI Endoscopy up 20%, GI EndoTherapy up 19% and Medical Service up 9%; SIS fourth-quarter revenue fell 7% to 85.1 billion yen, as Urology returned to 9% growth on the resumption of the majority of shipments while Respiratory declined 4%, Surgical Endoscopy declined 9% and Other Therapeutic Areas declined 33%. By region for the full year, GIS grew 13% in Europe, 13% in Asia and Oceania and 25% in Other, was flat in North America, and declined 11% in China and 5% in Japan.

Segment (billions of yen)	Item	FY2026 Full-year	FY2025 Full-year	YoY
GIS	Revenue	697.4	674.0	+3%
GIS	Operating profit	136.4	171.4	-20%
GIS	Adjusted operating profit	164.4	189.6	-13%
GIS	Adjusted operating margin	23.6%	28.1%	-4.6pp
SIS	Revenue	313.1	322.8	-3%
SIS	Operating profit (loss)	-15.0	15.3	–
SIS	Adjusted operating profit	0.8	23.6	-97%
SIS	Adjusted operating margin	0.3%	7.3%	-7.0pp
Elimination and Corporate	Operating profit (loss)	-23.8	-23.8	–
Consolidated Total	Revenue	1,010.7	997.3	+1%
Consolidated Total	Adjusted operating profit	143.3	188.5	-24%

Quality Remediation and Supply Recovery

Olympus states that all eight inspected facilities are progressing systematically through remediation, that quality management systems have been strengthened for durability, and that one-off remediation costs were substantially absorbed in FY2026. Some of the impacted products are back in the market, supply visibility for customers is improving, and the remaining products are described as on track for resumption. The company says it is engaging constructively with the FDA with a focus on achieving a durable, compliant end state. Expenses related to the quality and regulatory transformation project “Elevate” totaled 21.1 billion yen in FY2026 (SG&A expenses of 10.3 billion yen and other expenses of 10.8 billion yen), compared with 30.5 billion yen in FY2025.

FY2027 Guidance

For FY2027, Olympus guides to revenue of 1,055.0 billion yen to 1,076.0 billion yen, up 4.4% to 6.5% year on year (+1.5% to +3.5% after FX adjustment), operating profit of 136.5 billion yen to 155.5 billion yen and adjusted operating profit of 160.5 billion yen to 179.5 billion yen, implying an adjusted operating margin of 15.2% to 16.7% (up 1.0pp to 2.5pp). Adjusted EPS is guided at 106 yen to 119 yen, up 15% to 29%. The guidance assumes exchange rates of 155 yen per U.S. dollar, 181 yen per euro and 22.5 yen per CNY. Olympus expects phasing in which first-half growth is slower as ship-hold impacts continue to normalize and new operating model savings begin to materialize, with accelerated growth in the second half from ship-hold resolution, new product launches and building operating model savings. Margin drivers cited are the gradual decrease of one-off effects, structural efficiency gains under the new operating model and disciplined cost management.

Item (billions of yen, except EPS)	FY2027 Guidance	FY2026 Full-year (Actual)	vs FY2026
Revenue	1,055.0 to 1,076.0	1,010.7	+4.4% to +6.5%
Cost of sales	367.5 to 369.0	356.6	+3.1% to +3.5%
SG&A expenses	519.5 to 520.0	507.1	+2.4% to +2.5%
Operating profit	136.5 to 155.5	97.1	+40.6% to +60.1%
% of revenue	12.9% to 14.5%	9.6%	+3.3pp to +4.8pp
Adjusted operating profit	160.5 to 179.5	143.3	+12.0% to +25.3%
% of revenue	15.2% to 16.7%	14.2%	+1.0pp to +2.5pp
Profit attributable to owners of parent	95.5 to 109.0	68.2	+40.1% to +59.9%
EPS	¥90 to ¥102	¥61	+46% to +67%
Adjusted EPS	¥106 to ¥119	¥92	+15% to +29%

Segment (billions of yen)	Item	FY2027 Guidance	FY2026 Full-year (Actual)	vs FY2026
GIS	Revenue	744.0 to 749.0	697.4	+6.7% to +7.4%
GIS	Operating profit	173.5 to 180.0	136.4	+27.2% to +32.0%
GIS	Adjusted operating profit	181.5 to 188.0	164.4	+10.4% to +14.4%
SIS	Revenue	311.0 to 327.0	313.1	-0.7% to +4.4%
SIS	Operating profit (loss)	-2.5 to 10.0	-15.0	–
SIS	Adjusted operating profit	5.0 to 17.5	0.8	+517.4% to +2,061.1%
Elimination and Corporate	Operating profit (loss)	-34.5	-23.8	–
Consolidated Total	Revenue	1,055.0 to 1,076.0	1,010.7	+4.4% to +6.5%
Consolidated Total	Adjusted operating profit	160.5 to 179.5	143.3	+12.0% to +25.3%

R&D expenditures are guided at 119.0 billion yen for FY2027 after 109.9 billion yen in FY2026, capital expenditures at 95.0 billion yen after 92.2 billion yen, and depreciation and amortization at 68.0 billion yen after 67.2 billion yen.

Shareholder Returns

Olympus lists dividends of 30 yen per share as maintained, describing this as consistent with its commitment to stable shareholder returns, and its FY2027 dividend guidance is a year-end dividend of 30 yen per share. The company also plans share repurchases of up to 60 billion yen in FY2027, which it says reflects confidence in the business and commitment to shareholder value. Olympus states that it is shifting from a dividend-centric model to a more flexible framework balancing dividends with opportunistic share repurchases, and that as earnings power strengthens through FY2027 to FY2029 it will return capital more dynamically. Under its capital allocation policy, the company intends to maintain a BBB+ rating during the normal course, with flexibility to extend leverage to support strategic growth, including inorganic investment, within an investment-grade profile of BBB- or above. Financing cash flow was negative 87.6 billion yen in FY2026 due mainly to share repurchases and dividend payments, free cash flow was positive 13.2 billion yen and adjusted free cash flow was positive 53.5 billion yen; cash and cash equivalents ended the year at 188.0 billion yen and the equity ratio was 52.8%.

Medium-Term Plan and Topics

Olympus presents financial aspirations for FY2027 to FY2029 of revenue growth of 3-4-5% on a constant-currency basis, reaching 5% growth by FY2029; operating margin expansion of 100+ basis points year on year from FY2026; and adjusted EPS CAGR of more than 10% from FY2026, in each case adjusted for extraordinary items. These are underpinned by three strategic pillars: Innovation-Driven Growth, Simplicity and Accountability. Capital allocation priorities for FY2027 include strategic growth investment in innovation, GIS capabilities and selective M&A, with over a dozen product launches planned during the year.

The company is also applying an enterprise-wide portfolio framework under which every business is assessed against strategic fit, accretive growth and return on invested capital. Where ambitions are not met, Olympus says it will assess options to optimize performance and unlock greater value. On this basis it is initiating a strategic review of Surgical Endoscopy and Other Therapeutic Areas within SIS to explore a full range of options, with nothing off the table, no specific timeline and no pre-determined outcome, while stating that it remains fully committed to those customers and employees throughout the process.

This article is an analysis based on publicly available information and is not a recommendation to buy or sell any specific securities. Investment decisions are your own responsibility.